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 2 
Abstract 23 
Background 24 
Diagnosing cardioembolic stroke due to paroxysmal atrial fibrillation (PAF) is 25 
difficult, mainly due to a low detection rate. We evaluated whether left atrial 26 
volume, which can be simply measured using non-contrast chest computed 27 
tomography (CT-LAV), can contribute to the diagnosis of cardioembolic stroke due to 28 
PAF (PAF-CE). 29 
Methods 30 
Fifty-one consecutive patients with acute ischemic stroke within 24 h of onset were 31 
included in this study. Upon admission, we measured the left atrial diameter using 32 
transthoracic echocardiography (TTE-LAD) and CT-LAV. Patient background 33 
factors such as sex, age, and stroke risk factors; brain natriuretic peptide (BNP) 34 
value; and QTc interval were evaluated on admission. Utilities of BNP value, 35 
CT-LAV, and TTE-LAD in PAF-CE diagnosis were compared.  36 
Results 37 
Patients were classified into three groups: cerebral thrombosis (CTB) group 38 
including large-artery atherosclerosis and small-vessel occlusion (n=16), 39 
cardioembolic stroke due to non-valvular atrial fibrillation (AF-CE) group (n=20), 40 
and cardioembolic stroke due to paroxysmal atrial fibrillation (PAF-CE) group (n= 41 
15). BNP value was highest in the AF-CE group (240.5 pg/mL), followed by the 42 
PAF-CE (187.9 pg/mL) and CTB groups (35.0 pg/mL) (p<0.001)．There was a 43 
significant difference in TTE-LAD among the groups (AF-CE group, 43.8 mm; 44 
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PAF-CE group, 38.3 mm; CTB group, 34.1 mm) (p<0.001)．CT-LAV was higher in the 45 
AF-CE group (142 mm3) than in the PAF-CE (95.8 mm3) and CTB groups (95.8 mm3) 46 
(p<0.001). In differentiating PAF-CE, the area under the receiver operating 47 
characteristic curve was 0.867, 0.742, and 0.845 for BNP value, TTE-LAD, and 48 
CT-LAV, respectively. A cut-off CT-LAV value of ≥ 69.6 mm3 had a high diagnostic 49 
rate (>80% of sensitivity, specificity, positive predictive value, negative predictive 50 
value, and accuracy)． 51 
Conclusion 52 
 CT-LAV can be useful in PAF-CE diagnosis. Further studies with larger sample 53 
sizes are required to confirm our findings and determine better cut-off value for 54 
CT-LAV.  55 
 56 
57 
 4 
TEXT 58 
Introduction 59 
Cardioembolic stroke resulting from non-valvular atrial fibrillation (NVAF) 60 
(AF-CE) is known to result in poor outcomes, with many cases of in-hospital death1). 61 
There are also some cases of cerebral embolism in which the embolic source cannot 62 
be detected. These cases are described as embolic strokes of undetermined source 63 
(ESUS)2). When treating ESUS, the efficacy of antithrombotic agents for secondary 64 
prevention is unclear, and aspirin is currently recommended as the better choice3). 65 
However, in terms of causes of cardioembolic stroke, paroxysmal atrial fibrillation 66 
(PAF) is also known to be associated with a high primary risk for ischemic stroke4). 67 
Approximately 30% of cases of ESUS are thought to be caused by PAF5), and some 68 
patients require treatment with an anticoagulant agent as secondary prevention. 69 
Patients who do not exhibit NVAF at the time of ischemic stroke onset require 70 
long-term electrocardiography (ECG) monitoring. As the PAF detection rate for 24-h 71 
observation is only 2.9%, ECG monitoring must be performed for at least 72 h1). 72 
Therefore, various tests are performed to differentiate cardioembolic stroke due to 73 
PAF6)7). Transthoracic echocardiography (TTE) can be used to simply and 74 
noninvasively measure left atrial diameter (LAD). TTE-LAD dilatation is a finding 75 
that is suggestive of the presence of PAF8)9)10). However, there is a risk of 76 
measurement error resulting from difference in body position during testing or 77 
technical skill of the tester. 78 
As aortic arch calcification detected via chest computed tomography (CT) is also 79 
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known to be a risk factor for ischemic stroke11), many patients are assessed for 80 
ischemic stroke upon admission. 81 
Therefore, we measured simple left atrial volume (CT-LAV) with non-contrast 82 
chest CT in patients with acute ischemic stroke and investigated whether these 83 
values were useful in diagnosing cardioembolic stroke due to PAF (PAF-CE). 84 
 85 
Materials and methods  86 
 We retrospectively observed a total of 238 patients, including 158 with 87 
large-artery atherosclerosis and small-vessel occlusion and 80 with cardioembolic 88 
stroke due to NVAF or PAF who were hospitalized between April 2014 and March 89 
2018 at the Department of Neurology, Dokkyo Medical University Hospital, and 90 
whose condition developed within 24 h after admission. Ischemic stroke was 91 
classified using the Stop Stroke Study TOAST (SSS-TOAST)4) by Ay et al. Definitive 92 
diagnosis of PAF-CE was defined as meeting the ESUS diagnostic criteria2) upon 93 
admission and NVAF being noted during hospitalization. 94 
 Brain natriuretic peptide (BNP) levels were observed with blood testing during 95 
admission as well as QTc interval on ECG testing. Smoking, daily alcohol 96 
consumption, hypertension, dyslipidemia, and diabetes mellitus were evaluated as 97 
risk factors for cerebrovascular disease. We also investigated duration of 98 
hospitalization. 99 
We excluded patients who did not undergo BNP or QTc interval evaluation while 100 
being hospitalized, patients who did not undergo non-contrast chest CT or TTE 101 
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within 24 h after hospitalization, and those with cryptogenic stroke and stroke of 102 
other determined etiologies including ESUS. 103 
 104 
Evaluation of TTE-LAD and CT-LAV 105 
 TTE was performed using Vivid7 (GE Healthcare Japan), Vivid E9 (GE 106 
Healthcare Japan), Sonos-7500 (Philips，Japan), and iE33 (Philips，Japan). We used 107 
a sector-array probe in the parasternal long-axis view to measure TTE-LAD. 108 
 In non-contrast chest CT, we used Aquilion CXL (Canon Medical Systems, Japan), 109 
Aquilion One Vision edition (Canon Medical Systems, Japan), Sensation 40 110 
(Siemens Healthineers, Japan), and Sensation 64 (Siemens Healthineers, Japan) 111 
with the horizontal sectional view. Imaging conditions were mediastinal window 112 
(window level 50, window width 400) with slice thickness of 5 mm or 8 mm. CT-LAV 113 
was calculated with the following formula. 114 
CT-LAV (mm3)= longitudinal diameter (mm) × lateral diameter (mm)× number of 115 
slice × slice width (5 or 8) / 2 116 
 117 
Statistical analysis 118 
 Subjects were divided into a cerebral thrombosis (CTB) group (large-artery 119 
atherosclerosis and small-vessel occlusion), AF-CE group, and PAF-CE group. We 120 
analyzed sex, risk factors, duration of hospitalization, QTc interval, BNP level, 121 
TTE-LAD, and CT-LAV differences in each group. The statistical software used was 122 
SPSS Statistics version 25 (IBM). We used Pearson’s chi-square test to analyze 123 
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categorical variables. When analyzing continuous variables, we used the 124 
Mann-Whitney U test for comparisons between two groups and the Kruskal-Wallis 125 
test for comparisons between three groups. A P-value <0.05 indicated a statistically 126 
significant difference. 127 
We used the receiver operating characteristic (ROC) curve to investigate PAF-CE 128 
diagnosis sensitivity and specificity, positive predictive value (PPV), negative 129 
predictive value (NPV), and accuracy. In addition, we used univariate logistic 130 
regression to calculate odds ratios. 131 
 132 
Ethical standard 133 
 All procedures followed were in accordance with the ethical standards of the 134 
responsible committee on human experimentation (institutional and national) and 135 
the 1975 Declaration of Helsinki, as revised in 2008. The institutional review board 136 
of Dokkyo Medical University Hospital approved the study (IRB approved number, 137 
R-8-8). All patients provided written informed consent to participate. 138 
 139 
Results 140 
Investigation of three groups 141 
Of the total 238 patients, 16 were classified in the CTB group, 20 in the AF-CE 142 
group, and 15 in the PAF-CE group, and 187 patients were excluded. Male patients 143 
accounted for 68.8% of the CTB group, 40.0% of the AF-CE group, and 80.0% of the 144 
PAF-CE group, indicating that there were few men in the AF-CE group (p<0.05). 145 
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However, there were no differences noted for age, smoking, daily alcohol drinking, 146 
and duration of hospitalization, and no significant differences were observed for the 147 
prevalence of hypertension, dyslipidemia, or diabetes mellitus (Table 1). 148 
The QTc interval was 0.434 s (median) in the CTB group, 0.446 s in the AF-CE 149 
group, and 0.451 s in the PAF-CE group, indicating no significant differences 150 
(p=0.109). The BNP level was highest in the AF-CE group, at 240.5 pg/mL (median). 151 
It was elevated in the PAF-CE group, at 187.9 pg/mL, but within the normal range 152 
in the CTB group, at 35.0 pg/mL (p<0.001). TTE-LAD was 43.8 mm in the AF-CE 153 
group, 38.3 mm in the PAF-CE group, and 34.1 mm in the CTB group, indicating an 154 
intergroup difference (p<0.001). CT-LAV was highest in the AF-CE group, at 142 155 
mm3. It was 95.8 mm3 in the PAF-CE group and 53.7 mm3 in the CTB group 156 
(p<0.001) (Table 2). 157 
 158 
Post hoc analysis 159 
No significant differences were noted between the CTB group and the AF-CE 160 
group (p=0.474) and PAF-CE group (p=0.0860) in terms of sex (Pearson’s chi-square 161 
test). However, a difference was noted between the AF-CE and PAF-CE groups 162 
(p=0.0180). 163 
Significant differences were noted in the BNP levels between the CTB group with 164 
the AF-CE group and PAF-CE group. However, no difference was noted between the 165 
AF-CE and PAF-CE groups (p=0.298, Mann-Whitney U test). Meanwhile, 166 
significant differences were noted between all groups for TTE-LAD and CT-LAV 167 
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(Mann-Whitney U test) (Fig.1 A,B,C). 168 
 169 
Comparison of CTB group and PAF-CE group 170 
When diagnosing PAF-CE, ROC area under the curve was 0.867 for BNP level, 171 
0.742 for TTE-LAD, and 0.845 for CT-LAV, indicating that BNP level and CT-LAV 172 
were particularly useful (Fig.2). 173 
When the BNP cutoff value was set at 79.5 pg/mL or above, PAF-CE diagnosis 174 
could be made with a sensitivity of 86.7%, specificity of 81.3%, and accuracy of 175 
80.7%. Investigation of the diagnostic rate when the CT-LAV cutoff value was set at 176 
69.6 mm3 or higher indicated that sensitivity, specificity, PPV, and NPV were all 177 
80% or higher, with a higher level of 80.6% also achieved for accuracy. However, 178 
accuracy was low, at just 61.3% when the TTE-LAD cutoff value was set at 37.2 mm 179 
or greater (Table 3). 180 
The results of univariate logistic regression for each of these cutoff values 181 
indicated that BNP level (p=0.00185，odds ratio 19.5，95% confidence interval 3.01–182 
127) and CT-LAV (p=0.00171，odds ratio 17.3，95% confidence interval 2.92–103) 183 
were useful in diagnosing PAF-CE. However, TTE-LAD was not found to be useful 184 
(p=0.214). 185 
 186 
Discussion 187 
We investigated whether QTc interval, BNP level, TTE-LAD, and CT-LAV differed 188 
between the CTB, AF-CE, and PAF-CE groups and found that, while BNP level was 189 
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low in the CTB group, no differences were noted in the AF-CE and PAF-CE groups. 190 
We were also able to prove that TTE-LAD and CT-LAV were highest for the AF-CE 191 
group and high in the PAF-CE group, with a difference noted with the CTB group. 192 
BNP level and CT-LAV were found to be useful in the differential diagnosis of CTB 193 
and PAF-CE, which is important when selecting the method of secondary 194 
prevention12). 195 
Although our investigation did not reveal any differences in QTc interval. QTc 196 
interval prolongation is known to be a risk factor for NVAF13)14)15). Hoshino et al.7) 197 
measured QTc interval upon hospital admission in 744 ischemic stroke patients and 198 
found that PAF was likely to be detected in patients with a prolonged QTc interval. 199 
The cutoff value for this was reportedly 0.438 s. While we did not detect any 200 
statistically significant difference, we measured the QTc interval in the CTB group 201 
as being 0.434 s (median), while the QTc interval in the PAF-CE group was 202 
prolonged, at 0.451 s. Therefore, if the sample size was increased, it might be 203 
possible to show that QTc interval is useful in diagnosing PAF-CE.  204 
As BNP level reflects remodeling of the left atrium, it is known to become elevated 205 
prior to AF onset and associated with left atrial overload16). Furthermore, in cases of 206 
ischemic stroke in the acute stage, elevated BNP level is useful for predicting 207 
PAF-CE. Fujii et al.8) consider a BNP level of 144 pg/mL or higher to be of critical 208 
importance. However, Yoshioka et al.9) reported that a level of 90 pg/mL or higher is 209 
optimal for predicting PAF, and they have constructed PAF prediction scores using 210 
cutoff values of 50 pg/mL, 90 pg/mL, and 150 pg/mL or higher. Thus, there is no 211 
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optimal cutoff value for elevated BNP level in cases of acute ischemic stroke caused 212 
by PAF. A meta-analysis of approximately 2,800 patients indicated that BNP levels 213 
are more elevated in cases of AF-CE and PAF-CE than in cases of CTB even 72 h 214 
after onset6). In our study, which targeted cases of ischemic stroke within 24 h after 215 
onset, BNP measurement was also performed within 24 h after onset. Therefore, 216 
although median BNP levels in cases of CTB were somewhat elevated, at 35.0 217 
pg/mL, they were markedly elevated in cases of AF-CE (240.5 pg/mL) and PAF-CE 218 
(187.9 pg/mL). Moreover, in the differential diagnosis of CTB and PAF-CE, we found 219 
that PAF-CE could be diagnosed at a higher rate with a BNP level of 79.5 pg/mL or 220 
higher. While this BNP cutoff value is lower than that reported in previous studies, 221 
it is similar to the value reported by Yoshioka et al.9). 222 
In cases of NVAF, structural remodeling causes left atrial enlargement, dilatation, 223 
cell death, and fibrosis on weekly basis17). However, left atrial dilatation might not 224 
only be the result of atrial remodeling related to permanent arrhythmia. In fact, left 225 
atrial dilatation can arise as a result of thromboembolic cardiologic factors of the 226 
fibrillation unrelated to permanent or paroxysmal arrhythmia18)19). In addition, it 227 
has been reported that TTE-LAD can also become dilatated in cases of PAF-CE, and 228 
PAF-CE diagnosis scores using TTE-LAD have been proposed8)9)10). Fujii et al.8) have 229 
suggested that the cutoff value for TTE-LAD should be 38.0 mm while Yoshioka et 230 
al.9) suggested 40.0 mm. Suissa et al.10) proposed that a TTE-LAD value larger than 231 
the normal range should be considered to be a finding suggestive of PAF-CE. The 232 
results of our investigation indicated that TTE-LAD in the CTB group was within 233 
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the normal range, at 34.1 mm. However, the result was 43.8 mm for the AF-CE 234 
group and 38.3 mm for the PAF-CE group. When differentiating CTB and PAF-CE, 235 
TTE-LAD of 37.2 mm or larger is considered to be a finding suggestive of PAF-CE, 236 
and it is similar to the figure reported by Fujii et al. 8). However, accuracy was not 237 
overly high, at just 61.3%. Some patients with ischemic stroke cannot maintain a 238 
set position during testing, while others cannot follow the directions of the tester. 239 
Measurement errors may also arise as a result of the tester’s level of skill. These 240 
factors may have been the reason why a high TTE-LAD diagnostic rate was unable 241 
to be achieved. 242 
CT-LAV was 53.7mm3 in the CTB group, 142mm3 in the AF-CE group, and 95.8 243 
mm3 in the PAF-CE group. Like TTE-LAD, it was high in patients with NVAF and 244 
PAF. These results suggest that in patients in whom it is difficult to measure 245 
TTE-LAD, CT-LAV could be useful in diagnosing PAF-CE. We also demonstrated 246 
that at 69.3 mm3 or higher, PAF-CE could be diagnosed with a high accuracy of 247 
80.6%, which has almost the same diagnostic rate as that for BNP. To more 248 
accurately calculate CT-LAV with chest CT imaging, respiration and heart rate 249 
need to be synchronized. However, as no reports have attempted to perform PAF-CE 250 
diagnosis using normal chest CT, which is used to diagnose conditions such as aortic 251 
arch calcification and pneumonia, we believe that the fact that we were able to 252 
obtain findings suggestive of PAF-CE with CT-LAV could be very useful in clinical 253 
settings. 254 
Patients determined to have PAF while hospitalized were diagnosed as PAF-CE in 255 
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this study. However, the possibility that some patients exhibited PAF after being 256 
discharged cannot be ruled out. Moreover, in cases of insular infarctions, imbalance 257 
of sympathetic and parasympathetic activities can cause NVAF to develop20). 258 
Therefore, limitations of this study include the possibility that patients with PAF 259 
were included in the CTB group, possibility that cases of NVAF due to ischemic 260 
stroke were included in the AF-CE group and PAF-CE group, and small sample size. 261 
 262 
Conclusions 263 
 Like BNP level, CT-LAV might be useful in diagnosing PAF-CE. Furthermore, 264 
appropriate cutoff values need to be determined based on further investigation on a 265 
larger sample size. 266 
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Figure legend 332 
Figure 1 Post hoc analysis of BNP，TTE-LAD and CT-LAV 333 
 334 
A: BNP, B: TTE-LAD, C: CT-LAV 335 
BNP value was significantly lower in CTB group, but there was no difference 336 
between PAF-CE group and AF-CE group (Mann–Whitney U test). TTE-LAD and 337 
CT-LAV values were lowest in CTB group and highest in AF-CE group (Mann–338 
Whitney U test)． 339 
 340 
* p<0.05 ** p<0.01 *** p<0.001 341 
CTB, cerebral thrombosis; AF, non-valvular atrial fibrillation; PAF, paroxysmal 342 
atrial fibrillation; CE, cardioembolic stroke; BNP, brain natriuretic peptide; TTE, 343 
transthoracic echocardiography; LAD, left atrial diameter 344 
CT, computed tomography; LAV, left atrial volume 345 
 346 
Figure 2 ROC curve of BNP, TTE-LAD and CT-LAV in diagnosis of PAF-CE 347 
 348 
Area under the ROC curve was 0.867, 0.742 and 0.845 for BNP, TEE-LAD and 349 
CT-LAV, respectively. 350 
 351 
CTB, cerebral thrombosis; AF, non-valvular atrial fibrillation; PAF, paroxysmal 352 
atrial fibrillation; CE, cardioembolic stroke; BNP, brain natriuretic peptide; TTE, 353 
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transthoracic echocardiography; LAD, left atrial diameter; CT, computed 354 
tomography; LAV, left atrial volume; ROC curve, receiver operating characteristic 355 
curve 356 
 357 
 358 
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Table 1 Clinical background factors among CTB, AF-CE and PAF-CE groups 
 
 Groups  
  CTB 
(n=16) 
AF-CE 
(n=20) 
PAF-CE 
(n=15) 
p value 
Male (n, %) 11 (68.8) 8 (40.0) 12 (80.0) 0.0413* 
Age (years, median; range) 74 (43-89) 74.5 (66-92) 83 (64-93) 0.224 
Smoking (n, %) 2 (12.5) 3 (15.0) 1 (6.67) 0.746* 
Daily alcohol consumption (n, %) 2 (12.5) 4 (20.0) 3 (20.0) 0.809* 
Hypertension (n, %) 13 (81.3) 14 (70.0) 13 (86.7) 0.468* 
Dyslipidemia (n, %) 8 (50.0) 7 (35.0) 4 (26.7) 0.392* 
Diabetes mellitus (n, %) 3 (18.8) 5 (25.0) 3 (20.0) 0.889* 
Days of hospitalization (median; range) 15 (7-45) 19.5 (2-50) 16 (10-39) 0.231 
 
Kruskal-Wallis Test，*Pearson's chi-square test 
CTB, cerebral thrombosis; AF, non-valvular atrial fibrillation; PAF, paroxysmal atrial fibrillation;  
CE, cardioembolic stroke 
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Table 2 Comparison of four diagnostic markers among CTB, AF-CE and PAF-CE groups 
 
 Group  
  CTB (n=16) AF-CE (n=20) PAF-CE (n=15) p value 
QTc interval 
(sec, median; range) 
0.434  
(0.400-0.479) 
0.446 
(0.384-0.556) 
0.451 
(0.374-0.505) 
0.109 
BNP 
(pg/ml, median; range) 
35.0 
(6.6-406.2) 
240.5 
(84.1-609.3) 
187.9 
(41.7-687.8) 
<0.001 
TTE-LAD 
(mm, median; range) 
34.1 
(28.1-45.1) 
43.8 
(36.7-64.7) 
38.3 
(33.9-51.3) 
<0.001 
CT-LAV 
(mm3, median; range) 
53.7 
(19.9-106) 
142 
(90.1-411) 
95.8 
(35.2-138) 
<0.001 
 
Kruskal-Wallis Test 
CTB, cerebral thrombosis; AF, non-valvular atrial fibrillation; PAF, paroxysmal atrial fibrillation;  
CE, cardioembolic stroke;  
BNP, brain natriuretic peptide; TTE, transthoracic echocardiography; LAD, left atrial diameter; 
CT, computed tomography; LAV, left atrial volume 
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Table 3 Diagnostic rate of PAF-CE using BNP, TTE-LAD and CT-LAV 
 
 Sensitivity Specificity PPV NPV Accuracy 
BNP ≥ 79.5 pg/ml 86.7% 81.3% 76.5% 85.7% 80.7% 
TTE-LAD ≥ 37.2 mm 60.0% 62.5% 60.0% 62.5% 61.3% 
CT-LAV ≥ 69.6 mm3 80.0% 81.3% 80.0% 81.3% 80.6% 
 
AF, non-valvular atrial fibrillation; PAF, paroxysmal atrial fibrillation; CE, cardioembolic stroke; 
BNP, brain natriuretic peptide; TTE, transthoracic echocardiography; LAD, left atrial diameter; 
CT, computed tomography; LAV, left atrial volume; 
PPV, positive predictive value; NPV, negative predictive value 
 
 
